What are your thoughts on Penthrox getting approval in the USA. Considering the FDA withdrew it from the market in 2005. I realise that the methoxyflurane is administered at a much lower rate than previously, but the FDA is notorious for having high hurdles for drugs with significant side effects. Also do Abbott laboratories still have any rights to Pentrane as they stopped manufacturing in 1999 and will this affect MVP’s marketing rights. Based upon my calculations MVP has to have a growth rate of at least 40% over the next 5 years to justify its current P/E, is this achievable with a product that is used mainly for medical emergencies. It's current return on equity also doesn’t justify such a high price as it only justifies a share price of $0.86. Some comment would be greatly appreciated as analysis would indicate the shares are fully priced at the moment.
MVP Price at posting:
$1.80 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)